Pathobiology, Diagnosis, and Current Biomarkers in Neuromyelitis Optica Spectrum Disorders

Area of Science:

• Neuroimmunology
• Neuroinflammation

Background:

• Neuromyelitis optica spectrum disorder (NMOSD) is a CNS inflammatory condition affecting optic nerves and spinal cord.
• NMOSD shares clinical features with multiple sclerosis (MS) but has distinct causes and treatments, necessitating accurate diagnosis.

Purpose of the Study:

• To review the pathobiology, clinical presentation, and serological testing for NMOSD.
• To differentiate NMOSD from MS and summarize emerging therapies.

Main Methods:

• Review of scientific literature on NMOSD pathobiology, clinical features, and diagnostics.
• Analysis of serological biomarkers, including anti-aquaporin-4 (AQP4) and anti-myelin oligodendrocyte glycoprotein (MOG) antibodies.
• Discussion of diagnostic challenges, particularly in seronegative cases.

Main Results:

• NMOSD is characterized by inflammation and astrocyte destruction, primarily in AQP4-antibody-positive cases.
• Serological biomarkers, particularly AQP4-IgG, are key in diagnosing NMOSD.
• Distinguishing NMOSD from MS relies on clinical, imaging, and serological data.

Conclusions:

• Accurate diagnosis of NMOSD is essential due to its distinct pathology and treatment from MS.
• Serological testing and understanding biomarkers are vital for differentiating NMOSD.
• Advancements in therapies and biomarkers are anticipated to improve NMOSD management.